Goldman Sachs resumed coverage of Halozyme (HALO) with a Neutral rating and $55 price target The firm expects the hares to be range-bound until there is greater regulatory clarity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Closing Bell Movers: Progress Software slips 4% after earnings
- Halozyme added to Russell 1000 Index
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
- Merck granted review of Halozyme patent claims by PTAB